43 research outputs found
Recommended from our members
The effects of natural convection on low temperature combustion
When a gas undergoes an exothermic reaction in a closed vessel, spatial temperature gradients can develop. If these gradients become sufficiently large, the resulting buoyancy forces will move the gas, i.e. there is natural convection. The nature of the resulting flow is determined by the Rayleigh number, Ra = (ÎČ g ÎT L^3) / (Îș Îœ). The evolution of such a system will depend on the interactions of natural convection, diffusion of both heat and chemical species, and chemical reaction. This study is concerned with a gas-phase system undergoing Salânikovâs reaction: P â A â B, in the presence of natural convection. This kinetic scheme is used as a simplified representation of a cool flame, which is a feature of the low temperature combustion of a hydrocarbon vapour. Salânikovâs reaction is one of the simplest to display thermokinetic oscillations, such as those seen in cool flames. The behaviour of Salânikovâs reaction in the presence of natural convection was investigated using a combination of analytical and numerical techniques. First, a numerical model was developed to compute the temperature, velocity and concentrations when a simple exothermic reaction occurs in a spherical batch reactor, the results of which could be compared with previous experimental measurements. Subsequently, a scaling analysis of Salânikovâs reaction proceeding in a spherical reactor was performed. This yielded significant insight into the general behaviour of this and similar systems. The forms of the analytical scales were confirmed through comparison with the results from numerical simulations. These scales were used to predict how the system responds to changes in certain key process variables, such as the pressure and the size of the reactor. It was shown that the behaviour of this system is governed by the ratios of the characteristic timescales for diffusion, reaction and natural convection. These ratios were used to define a regime diagram describing the system. The behaviour in different parts of this regime diagram was characterised and regions in which oscillations occur were identified.Engineering and Physical Sciences Research Council and Society of Chemical Industr
EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation
Adoptive immunotherapy with EpsteinâBarr virus (EBV)-specific T cells is an effective treatment for relapsed or refractory EBV-induced post-transplant lymphoproliferative disorders (PTLD) with overall survival rates of up to 69%. EBV-specific T cells have been conventionally made by repeated stimulation with EBV-transformed lymphoblastoid cell lines (LCL), which act as antigen-presenting cells. However, this process is expensive, takes many months, and has practical risks associated with live virus. We have developed a peptide-based, virus-free, serum-free closed system to manufacture a bank of virus-specific T cells (VST) for clinical use. We compared these with standard LCL-derived VST using comprehensive characterization and potency assays to determine differences that might influence clinical benefits. Multi-parameter flow cytometry revealed that peptide-derived VST had an expanded central memory population and less exhaustion marker expression than LCL-derived VST. A quantitative HLA-matched allogeneic cytotoxicity assay demonstrated similar specific killing of EBV-infected targets, though peptide-derived EBV T cells had a significantly higher expression of antiviral cytokines and degranulation markers after antigen recall. High-throughput T cell receptor-beta (TCRÎČ) sequencing demonstrated oligoclonal repertoires, with more matches to known EBV-binding complementary determining region 3 (CDR3) sequences in peptide-derived EBV T cells. Peptide-derived products showed broader and enhanced specificities to EBV nuclear antigens (EBNAs) in both CD8 and CD4 compartments, which may improve the targeting of highly expressed latency antigens in PTLD. Importantly, peptide-based isolation and expansion allows rapid manufacture and significantly increased product yield over conventional LCL-based approaches.</p
Human umbilical cord perivascular cells improve human pancreatic islet transplant function by increasing vascularization
Islet transplantation is an efficacious therapy for type 1 diabetes; however, islets from multiple donor pancreata are required, and a gradual attrition in transplant function is seen. Here, we manufactured human umbilical cord perivascular mesenchymal stromal cells (HUCPVCs) to Good Manufacturing Practice (GMP) standards. HUCPVCs showed a stable phenotype while undergoing rapid ex vivo expansion at passage 2 (p2) to passage 4 (p4) and produced proregenerative factors, strongly suppressing T cell responses in the resting state and in response to inflammation. Transplanting an islet equivalent (IEQ):HUCPVC ratio of 1:30 under the kidney capsule in diabetic NSG mice demonstrated the fastest return to normoglycemia by 3 days after transplant: Superior glycemic control was seen at both early (2.7 weeks) and later stages (7, 12, and 16 weeks) versus ratios of 1:0, 1:10, and 1:50, respectively. Syngeneic islet transplantation in immunocompetent mice using the clinically relevant hepatic portal route with a marginal islet mass showed that mice transplanted with an IEQ:HUCPVC ratio of 1:150 had superior glycemic control versus ratios of 1:0, 1:90, and 1:210 up to 6 weeks after transplant. Immunodeficient mice transplanted with human islets (IEQ:HUCPVC ratio of 1:150) exhibited better glycemic control for 7 weeks after transplant versus islet transplant alone, and islets transplanted via the hepatic portal vein in an allogeneic mouse model using a curative islet mass demonstrated delayed rejection of islets when cotransplanted with HUCPVCs (IEQ:HUCPVC ratio of 1:150). The immunosuppressive and proregenerative properties of HUCPVCs demonstrated long-term positive effects on graft function in vivo, indicating that they may improve long-term human islet allotransplantation outcomes
Safety profile of autologous macrophage therapy for liver cirrhosis
This work was supported by a Medical Research Council UK grant (Biomedical Catalyst Major Awards Committee; reference MR/M007588/1) to S.J. Forbes. We thank Z.M. Younossi (Center for Outcomes Research in Liver Diseases, Washington, DC, USA) for academic use of the CLDQ instrument and L.J. Fallowfield (Sussex Health Outcomes Research & Education in Cancer (SHORE-C), University of Sussex, UK) for advice about health-related quality of life assessment.Peer reviewedPostprintPostprintPostprintPostprin
Allogeneic Ex Vivo Expanded Corneal Epithelial Stem Cell Transplantation: A Randomized Controlled Clinical Trial
APPEAL FROM THE DECREE OF DIVORCE EXECUTED AND ENTERED BY THE THIRD JUDICIAL DISTRICT COURT. IN AND FOR SALT LAKE COUNTY. STATE OF UTAH. THE HONORABLE FRANK G. NOEL. PRESIDIN
Phenotypic and functional characterization of macrophages with therapeutic potential generated from human cirrhotic monocytes in a cohort study
AbstractBackground aimsMacrophages have complex roles in the liver. The aim of this study was to compare profiles of human monocyte-derived macrophages between controls and cirrhotic patients, to determine whether chronic inflammation affects precursor number or the phenotype, with the eventual aim to develop a cell therapy for cirrhosis.MethodsInfusion of human macrophages in a murine liver fibrosis model demonstrated a decrease in markers of liver injury (alanine transaminase, bilirubin, aspartate transaminase) and fibrosis (transforming growth factor-ÎČ, α-smooth muscle actin, phosphatidylserine receptor) and an increase in markers of liver regeneration (matrix metalloproteinases [MMP]-9, MMP-12 and TNF-related weak inducer of apoptosis). CD14+ monocytes were then isolated from controls. Monocytes were matured into macrophages for 7 days using a Good Manufacturing Practiceâcompatible technique.ResultsThere was no significant difference between the mean number of CD14+ monocytes isolated from cirrhotic patients (n = 9) and controls (n = 10); 2.8 ± SEM 0.54 à 108 and 2.5 ± 0.56 à 108, respectively. The mean yield of mature macrophages cultured was also not significantly different between cirrhotic patients and controls (0.9 à 108 ± 0.38 à 108, with more than 90% viability and 0.65 à 108 ± 0.16 à 108, respectively. Maturation to macrophages resulted in up-regulation of a number of genes (MMP-9, CCL2, interleukin [IL]-10 and TNF-related weak inducer of apoptosis). A cytokine and chemokine polymerase chain reaction array, comparing the control and cirrhotic macrophages, revealed no statistically significant differences.ConclusionsMacrophages can be differentiated from cirrhotic patients' apheresis-derived CD14 monocytes and develop the same pro-resolution phenotype as control macrophages, indicating their suitability for clinical therapy